We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
-1.4%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$241M
AUM Growth
-$110M
Cap. Flow
-$100M
Cap. Flow %
-41.68%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$97.4M
2
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$2.83M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$72.3M 30.07%
1,554,744
– –
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$52.4M 21.79%
273,077
– –
NSTG
3
DELISTED
NanoString Technologies, Inc.
NSTG
$40.3M 16.77%
3,959,440
– –
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$33.4M 13.88%
2,371,328
-207,734
-8% -$2.83M
TLOG
5
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
$20.3M 8.46%
4,644,705
– –
VBIV
6
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$12.9M 5.37%
165,703
– –
EVFM
7
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$8.8M 3.66%
11,905
– –
AERI
8
DELISTED
Aerie Pharmaceuticals
AERI
– –
-3,338,067
Closed -$97.4M

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q1 2015 Portfolio in Review

As of Q1 2015, Clarus Ventures held 8 positions worth $241M, down 31% from $350M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures withdrew a net $100M in Q1 2015, closing 1 position and reducing 1 holding. Its most notable exit was Aerie Pharmaceuticals, an estimated $97.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Clarus Ventures's biggest Q1 2015 reduction was Oxford Immunotec Global PLC Ordinary Shares, cutting an estimated $2.83M.
  • Clarus Ventures fully exited Aerie Pharmaceuticals in Q1 2015, selling an estimated $97.4M.
  • Clarus Ventures's ten largest holdings make up 100% of its $241M portfolio in Q1 2015.
  • Clarus Ventures opened 0 new positions and closed 1 in Q1 2015.
  • Clarus Ventures's portfolio value fell 31% quarter-over-quarter to $241M.

Based on Clarus Ventures's 13F filing for Q1 2015, filed 12 May 2015.